Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
VISEN Pharmaceuticals's operating assets for the quarter that ended in Jun. 2026 was €48.85 Mil. VISEN Pharmaceuticals's operating liabilities for the quarter that ended in Jun. 2026 was €5.02 Mil. VISEN Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was €118.50 Mil. Therefore, VISEN Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was 0.37.
VISEN Pharmaceuticals Scaled Net Operating Assets Related Terms
VISEN Pharmaceuticals Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for VISEN Pharmaceuticals's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals Scaled Net Operating Assets Chart
FRA:T06 vs ZTS: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.37 mean?
VISEN Pharmaceuticals (FRA:T06) has a Scaled Net Operating Assets of 0.37 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on VISEN Pharmaceuticals and its competitors.
Is VISEN Pharmaceuticals' Scaled Net Operating Assets too high?
VISEN Pharmaceuticals' current Scaled Net Operating Assets is 0.37. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Scaled Net Operating Assets compare to ZTS?
VISEN Pharmaceuticals' Scaled Net Operating Assets of 0.37 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on VISEN Pharmaceuticals and its competitors. VISEN Pharmaceuticals's current Scaled Net Operating Assets is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Scaled Net Operating Assets of 0.37. The current Scaled Net Operating Assets is 0.37. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Scaled Net Operating Assets is 0.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
